European Pharmaceutical Review

DECEMBER 22, 2022

Construction of MITC is expected to commence in early 2023, with the first mRNA vaccine expected to be produced in the UK in 2025. Steve Barclay, Health and Social Care Secretary added: “By boosting our onshore vaccine manufacturing capability, we are a step closer to becoming the leading global hub for life sciences.

Manufacturing 127

Manufacturing Government Leads Pharmaceutical 127

pharmaphorum

OCTOBER 9, 2022

UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal.

Leads 57

Leads Healthcare Healthcare 57

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

European Pharmaceutical Review

NOVEMBER 23, 2023

For example, CPI asserted that lead times for clinical trial materials are hindering new therapies being developed. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025. This is a first-of-its-kind collaboration for the pharma industry.

Manufacturing 82

Manufacturing Medicine Government Pharmaceutical 82

Pharmaceutical Technology

JUNE 20, 2023

“It will be an iconic addition to the world-leading Melbourne biomedical precinct and will equip us with the facilities and resources we need to get ahead of the next pandemic.” Demolition of the existing buildings on the site will commence next year, and construction work on the new building will begin in 2025.

Government 52

Government Leads 52

PM360

OCTOBER 25, 2023

According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development (R&D) and commercial functions by 2025. This lack of understanding may lead to resistance or wariness of new technology. Regulatory concerns.

Management 105

Management Medical Pharma Pharmaceutical 105

Pharmaceutical Technology

APRIL 17, 2023

The proposed merger is expected to realise at least $50m of net transaction cash proceeds, set to be used to finance the merged entity’s business as well as Phase II trials and operations through the second quarter of 2025. The merger is scheduled to be completed by the third quarter of 2023.

Patients 98

Patients Leads Pharmaceutical Marketing 98

Pharmaceutical Technology

JUNE 8, 2023

Mendus has entered an alliance with NorthX Biologics to co-establish a cell therapy manufacturing unit for its lead asset, vididencel, in Sweden. The cell therapy facility will be used for the large-scale production of vididencel, Mendus’s lead programme. All operations will take place there until the second quarter of 2025.

Manufacturing 52

Manufacturing Leads Patients Medicine 52

European Pharmaceutical Review

SEPTEMBER 26, 2022

The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025. to lead R&D organization and drive continued pipeline advancement… The post AbbVie Cork facility €60 million expansion appeared first on European Pharmaceutical Review. AbbVie announces Michael Severino, M.D.

Manufacturing 81

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 81

Pharmaceutical Technology

DECEMBER 21, 2022

Planned to be operational by 2025, the construction of the facility is anticipated to begin early next year. Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

pharmaphorum

JANUARY 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50

Pharma 84

Pharma Biopharma Management Medicine 84

European Pharmaceutical Review

MARCH 6, 2023

Harwell, the UK’s leading science and innovation campus in Oxfordshire will be the location of the Moderna Innovation and Technology Centre (MITC). The Moderna Innovation and Technology Centre is expected to become operational in 2025. Moderna is the latest organisation to join Harwell’s Health Tech cluster.

Manufacturing 82

Manufacturing Food and Drug Administration Government Food 82

European Pharmaceutical Review

APRIL 26, 2023

Once completed, the MITC is expected to become operational in 2025. Harwell Science and Innovation Campus Harwell is the UK’s leading science and innovation campus. Moderna’s investment will create hundreds of jobs during construction and operation.

Manufacturing 52

Manufacturing Government Management Leads 52

Pharmaceutical Technology

MAY 2, 2023

Marker Therapeutics CEO Juan Vera stated: “Marker’s management and impartial members of the board worked with John Wilson and CellReady to develop a very creative and non-dilutive plan that provides Marker with the financial runway to pursue its clinical priorities through the end of 2025. “At

Manufacturing 52

Manufacturing Leads Management Pharmaceutical 52

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. A lack of good antigens to target in AML is widely believed to have caused this dearth of effective cell therapies.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

SEPTEMBER 14, 2022

SparingVision’s lead candidates are both targeting inherited retinal diseases (IRDs), a group which already has a gene therapy on the market in Novartis’ Luxturna (voretigene neparvovec), which was approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, a group which includes a small group of RP patients.

Safety 52

Safety Leads Patients FDA 52

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. There are more than 200 lung disorders that can lead to pulmonary fibrosis.

Recruitment 93

Recruitment Prospecting Marketing Patients 93

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.

Food and Drug Administration 93

Food and Drug Administration Side effects Leads Patients 93

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.

Food and Drug Administration 92

Food and Drug Administration Side effects Leads Patients 92

Pharmaceutical Technology

MAY 5, 2023

The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025. Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

Leads 52

Leads Manufacturing Management Pharmaceutical 52

LEVO Health

MAY 7, 2024

Between 2021 and 2025, the healthcare influencer market was expected to grow by over 10%. These relationships foster deeper trust and may lead to more authentic endorsements of healthcare services or products. This may lead to more ROI-focused spending.

Healthcare 52

Healthcare Healthcare Marketing Healthcare Provider 52

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Sales 106

Sales Biopharma Medicine Patients 106

European Pharmaceutical Review

AUGUST 1, 2022

Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead. Common clinical trial practices exclude up to a quarter of the US population based on disability status, according to BMS.

Food and Drug Administration 108

Food and Drug Administration Medical Medicine Engineering 108

Pharmaceutical Technology

JANUARY 30, 2023

Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5 Likewise, Moderna’s Spikevax, the second leading COVID-19 vaccine with 19.5

Sales 52

Sales Competition Leads Medicine 52

Pharmaceutical Technology

AUGUST 11, 2022

The proceeds from the business combination will be utilised to advance the pipeline of Disc to clinical trials and offer funding into 2025. Present Disc Medicine CEO and president John Quisel will lead the merged company along with other management team members. It will be valued at nearly $175m in cash or cash equivalents.

Medicine 59

Medicine Transportation Patients Healthcare 59

pharmaphorum

JULY 22, 2022

Co-Chaired by: Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda. In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Sponsored by Ecolab, Elis Cleanroom, Innerspace, Microgenetics, Novatek. Advances in Pharma 4.0

Pharmaceutical 52

Pharmaceutical Engineering Management Media 52

pharmaphorum

AUGUST 17, 2022

The deal will see Atomwise identify, synthesize, and advance lead compounds for up to five drug targets that will then be exclusively Sanofi’s to develop. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025.

Medicine 78

Medicine Pharma Engineering Sales 78

pharmaphorum

SEPTEMBER 29, 2022

“These preliminary results…reaffirm that CirrhoCare is feasible for community management of decompensated cirrhosis patients,” said lead investigator Prof Raj Mookerjee, a consultant hepatologist at University College London. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

PM360

SEPTEMBER 21, 2023

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Manufacturers will want to understand the changing plan economics under Part D redesign in addition to the coming effects from drug negotiation as they embark on contract negotiations for the 2025 plan year and beyond.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

JANUARY 23, 2024

R&D spend is steadily growing and is expected to reach approximately $200 billion by 2025. She has extensive experience working with the business intelligence teams of leading pharmaceutical companies on topics such as R&D productivity , portfolio risk and protocol complexity.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

Quantified

SEPTEMBER 21, 2023

According to Gartner, 75% of B2B sales organizations will augment traditional playbooks with AI by 2025 despite the current low adoption rate. Use Cases for AI Tools for Sales The sales cycle is often divided into seven stages, from lead generation to completing a sale. They can segment leads according to product line.

Sales 52

Sales Prospecting Training Sales tools 52

pharmaphorum

NOVEMBER 1, 2022

billion by 2025, growing at a CAGR of 7.5%. Benefits of attending: Explore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81

Pharmacology 52

Pharmacology Medicine Networking Pharma 52

European Pharmaceutical Review

MARCH 7, 2024

Last month, construction began on Europe’s first industrial-scale facility dedicated to the production of lead-212 based radioligand therapies.

Manufacturing 52

Manufacturing Food and Drug Administration Marketing Management 52

pharmaphorum

OCTOBER 12, 2022

The research collaboration will explore the use of the two companies’ technologies side by side to find targets across a range of human diseases for an initial six-month period, and if successful could lead to a long term, strategic level partnership, according to the partners.

Pharma 62

Pharma Training Networking Leads 62

pharmaphorum

OCTOBER 13, 2022

However, there is a problem facing the treatment of osteoporosis, and it is the lack of research into new therapies, leading to a limited pipeline of new treatments coming through. It is projected that this could lead to a situation where the economic burden would be “unsustainable for most healthcare systems,” he concluded.

Marketing 87

Marketing Healthcare Healthcare Leads 87

pharmaphorum

JULY 4, 2022

Today, together with our partners, we announce our renewed drive for innovative and patient-centred research in the UK-wide 2022 – 2025 plan #ResearchSavesLives [link] pic.twitter.com/LKr5OFFs3h. — NIHR Research (@NIHRresearch) June 30, 2022.

Government 52

Government Patients Medicine Healthcare 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.

Marketing 98

Marketing Pharma Healthcare Healthcare 98